Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (formerly Argonaut Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: RXi is a discovery-stage biopharmaceutical company focused on developing therapeutics based on RNA interference (RNAi) for neurological diseases (e.g., ALS), metabolic diseases (e.g., obesity, type 2 diabetes), and oncology. The company was formed in 2006 and commenced operations in January 2007 following the contribution of RNAi assets from its parent, CytRx Corporation. As of the filing date, the company had no commercial products and generated no revenue.
Key Financial Metrics
| Metric | 2007 (Successor) | 2006 (Predecessor) |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expense | $6,747,000 | $1,772,000 |
| General & Administrative Expense | $4,666,000 | $633,000 |
| Operating Loss | $(11,413,000) | $(2,405,000) |
| Net Loss | $(10,990,000) | $(2,405,000) |
| Cash and Cash Equivalents (Year End) | $1,763,000 | $2,000 |
| Short-Term Investments | $9,952,000 | $0 |
| Total Assets | $12,147,000 | $2,000 |
| Working Capital | $10,413,000 | $2,000 |
Note: 2006 figures represent "carved-out" predecessor financials allocated from CytRx Corporation. 2007 figures represent the "successor" entity.
Material Changes vs. Prior Period
- Operational Status: Transitioned from a carved-out division of CytRx (Predecessor) to an independent operating subsidiary (Successor) in January 2007, resulting in a significant increase in direct operating expenses.
- Expense Growth: Net loss increased by approximately 358% to $11.0 million in 2007 compared to $2.4 million in 2006. This was driven by a $4.9 million increase in R&D expenses (due to lab setup, hiring, and license fees) and a $4.0 million increase in G&A expenses (due to public company formation costs and staff expansion).
- Liquidity: Cash and short-term investments surged from $2,000 in 2006 to $11.7 million in 2007, primarily due to a $17.0 million equity investment from CytRx in April 2007.
- Capital Structure: Issued significant common stock to CytRx for asset contributions and cash investments, and to the University of Massachusetts Medical School (UMMS) for intellectual property licenses.
Guidance, Outlook, and Risks
Outlook and Guidance: The company expects to incur significant operating losses for the foreseeable future. Management believes current capital resources ($11.7 million in cash and investments) are sufficient to fund operations through the first quarter of 2009. Planned expenditures for this period include approximately $6.3 million for R&D and $4.6 million for G&A. The company anticipates no revenue from product sales in the foreseeable future.
Key Risks and Contingencies:
- Going Concern: The company is a development-stage entity with no revenue. Continued operations depend on securing additional financing through equity or debt offerings, which may not be available on acceptable terms.
- Technology Risk: RNAi therapeutics are unproven; the company has no products in clinical trials and faces significant scientific and regulatory hurdles.
- Intellectual Property: The company relies heavily on licensed technology from third parties (primarily UMMS). Failure to maintain these licenses or inability to secure new ones would halt development.
- Internal Controls: The independent auditor identified material weaknesses in internal controls over financial reporting, specifically regarding the timely reconciliation of ledgers and the preparation/review of stock option expense calculations.
- Related Party Dependence: CytRx Corporation owns approximately 49% of the outstanding common stock and has preemptive rights to maintain this percentage, which could impact future financing and control.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $11.7 million cash position and the projected burn rate to confirm the ability to operate through Q1 2009.
- License Obligations: Review the specific milestone and royalty payment obligations to UMMS and other licensors, particularly the requirement to expend at least $3.3 million annually on development.
- Internal Controls Remediation: Assess the progress made in remedying the material weaknesses in financial reporting identified by the auditor.
- Related Party Transactions: Scrutinize the terms of the agreements with CytRx, including the reimbursement of expenses and the preemptive rights that may dilute future investors.
- Valuation Assumptions: Review the third-party valuations used to determine the fair value of stock issued for licenses and services, as the company had no public trading market during the reporting period.